162 related articles for article (PubMed ID: 34173009)
1. The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells.
Braun C; Schlaweck S; Daecke SN; Brossart P; Heine A
Cancer Immunol Immunother; 2021 Dec; 70(12):3693-3700. PubMed ID: 34173009
[TBL] [Abstract][Full Text] [Related]
2. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
Palazzo A; Herter S; Grosmaire L; Jones R; Frey CR; Limani F; Bacac M; Umana P; Oldham RJ; Marshall MJE; Cox KL; Turaj AH; Cragg MS; Klein C; Carter MJ; Tannheimer S
J Immunol; 2018 Apr; 200(7):2304-2312. PubMed ID: 29453281
[TBL] [Abstract][Full Text] [Related]
3. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
Hanna BS; Roessner PM; Scheffold A; Jebaraj BMC; Demerdash Y; Öztürk S; Lichter P; Stilgenbauer S; Seiffert M
Leukemia; 2019 Jun; 33(6):1427-1438. PubMed ID: 30573773
[TBL] [Abstract][Full Text] [Related]
4. Idelalisib inhibits osteoclast differentiation and pre-osteoclast migration by blocking the PI3Kδ-Akt-c-Fos/NFATc1 signaling cascade.
Yeon JT; Kim KJ; Son YJ; Park SJ; Kim SH
Arch Pharm Res; 2019 Aug; 42(8):712-721. PubMed ID: 31161369
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
Stock S; Übelhart R; Schubert ML; Fan F; He B; Hoffmann JM; Wang L; Wang S; Gong W; Neuber B; Hückelhoven-Krauss A; Gern U; Christ C; Hexel M; Schmitt A; Schmidt P; Krauss J; Jäger D; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2019 Sep; 145(5):1312-1324. PubMed ID: 30737788
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy.
Ko J; Kim JY; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2018 Sep; 59(11):4477-4485. PubMed ID: 30193323
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of dendritic cell differentiation and function by oxidized phospholipids.
Blüml S; Zupkovitz G; Kirchberger S; Seyerl M; Bochkov VN; Stuhlmeier K; Majdic O; Zlabinger GJ; Seiser C; Stöckl J
Blood; 2009 Dec; 114(27):5481-9. PubMed ID: 19864645
[TBL] [Abstract][Full Text] [Related]
8. Theoretical studies on the selectivity mechanisms of PI3Kδ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation.
Zhu J; Ke K; Xu L; Jin J
J Mol Model; 2019 Jul; 25(8):242. PubMed ID: 31338599
[TBL] [Abstract][Full Text] [Related]
9. Idelalisib activates AKT via increased recruitment of PI3Kδ/PI3Kβ to BCR signalosome while reducing PDK1 in post-therapy CLL cells.
Mamidi MK; Mahmud H; Maiti GP; Mendez MT; Fernandes SM; Vesely SK; Holter-Chakrabarty J; Brown JR; Ghosh AK
Leukemia; 2022 Jul; 36(7):1806-1817. PubMed ID: 35568768
[TBL] [Abstract][Full Text] [Related]
10. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
11. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
12. The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
Chellappa S; Kushekhar K; Munthe LA; Tjønnfjord GE; Aandahl EM; Okkenhaug K; Taskén K
J Immunol; 2019 Mar; 202(5):1397-1405. PubMed ID: 30692213
[TBL] [Abstract][Full Text] [Related]
13. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
Lim EL; Cugliandolo FM; Rosner DR; Gyori D; Roychoudhuri R; Okkenhaug K
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875319
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma.
Gopal AK; Fanale MA; Moskowitz CH; Shustov AR; Mitra S; Ye W; Younes A; Moskowitz AJ
Ann Oncol; 2017 May; 28(5):1057-1063. PubMed ID: 28327905
[TBL] [Abstract][Full Text] [Related]
15. Idelalisib Rescues Natural Killer Cells from Monocyte-Induced Immunosuppression by Inhibiting NOX2-Derived Reactive Oxygen Species.
Akhiani AA; Hallner A; Kiffin R; Aydin E; Werlenius O; Aurelius J; Martner A; Thorén FB; Hellstrand K
Cancer Immunol Res; 2020 Dec; 8(12):1532-1541. PubMed ID: 32967913
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation.
Toniolo PA; Liu S; Yeh JE; Moraes-Vieira PM; Walker SR; Vafaizadeh V; Barbuto JA; Frank DA
J Immunol; 2015 Apr; 194(7):3180-90. PubMed ID: 25725100
[TBL] [Abstract][Full Text] [Related]
17. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.
Yang Q; Chen LS; Ha MJ; Do KA; Neelapu SS; Gandhi V
Clin Cancer Res; 2017 Jan; 23(1):181-192. PubMed ID: 27342398
[TBL] [Abstract][Full Text] [Related]
18. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
Shah A; Mangaonkar A
Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
[TBL] [Abstract][Full Text] [Related]
19. PI3Kδ inhibitors for the treatment of cancer: a patent review (2015-present).
Feng Y; Cu X; Xin M
Expert Opin Ther Pat; 2019 Dec; 29(12):925-941. PubMed ID: 31670985
[No Abstract] [Full Text] [Related]
20. The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential.
Barrachina MN; Izquierdo I; Hermida-Nogueira L; Morán LA; Pérez A; Arroyo AB; García-Barberá N; González-Conejero R; Troitiño S; Eble JA; Rivera J; Martínez C; Loza MI; Domínguez E; García Á
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33804911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
